Payment overview · 2025
General Payments
$755.72
41 reported records · 15 companies
Healthcare provider profile · identity verified
David A. Glusko, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MEYERSDALE, PA · NPI 1295737518
Verified facts
What the public records show
CMS Open Payments records show David A. Glusko, D.O. received $755.72 in general payments during 2025 across 41 reported records.
GlaxoSmithKline, LLC. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $137.79 | 18.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.67 | 13.7% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $91.12 | 12.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.15 | 10.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $71.40 | 9.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.34 | 9.3% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $44.66 | 5.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.73 | 4.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.61 | 3.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.13 | 2.4% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $18.05 | 2.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.37 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.13 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.07 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.50 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $705.77 | 40 |
| Long term medical supply or device loan | $49.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $127.89 | 8 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $82.15 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $71.40 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.31 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.18 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.17 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $9.90 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $9.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 225 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 130 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
225 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
225 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 640 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 538 | 106 |
| Lisinopril | Lisinopril | 481 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 73 |
| Furosemide | Furosemide | 287 | 59 |
| Potassium Chloride | Potassium Chloride | 269 | 53 |
| Losartan Potassium | Losartan Potassium | 262 | 52 |
| Gabapentin | Gabapentin | 258 | 47 |
| Metformin Hcl | Metformin Hcl | 257 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 228 | 60 |
| Eliquis | Apixaban | 225 | 40 |
| Meloxicam | Meloxicam | 221 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 50 |
| Trulicity | Dulaglutide | 198 | 26 |
| Omeprazole | Omeprazole | 197 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 49 |
| Metformin Hcl Er | Metformin Hcl | 187 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 43 |
| Carvedilol | Carvedilol | 168 | 42 |
| Valsartan | Valsartan | 156 | 33 |
| Prednisone | Prednisone | 147 | 95 |
| Sertraline Hcl | Sertraline Hcl | 144 | 26 |
| Simvastatin | Simvastatin | 135 | 31 |
| Alprazolam | Alprazolam | 133 | 29 |
| Montelukast Sodium | Montelukast Sodium | 132 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 36 |
| Jardiance | Empagliflozin | 130 | 22 |
| Lorazepam | Lorazepam | 113 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 112 | 20 |
| Famotidine | Famotidine | 99 | 21 |
| Glimepiride | Glimepiride | 99 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 19 |
| Azithromycin | Azithromycin | 97 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 20 |
| Mounjaro | Tirzepatide | 86 | 12 |
| Clonazepam | Clonazepam | 83 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 18 |
| Allopurinol | Allopurinol | 81 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | 18 |
| Tramadol Hcl | Tramadol Hcl | 76 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 15 |
| Ozempic | Semaglutide | 69 | 12 |
| Synthroid | Levothyroxine Sodium | 69 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 12 |
| Donepezil Hcl | Donepezil Hcl | 63 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 17 |
| Glipizide | Glipizide | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Finasteride | Finasteride | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 14 |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | suppressed |
| Spironolactone | Spironolactone | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 12 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Tradjenta | Linagliptin | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Celecoxib | Celecoxib | 44 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 34 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 14 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 12 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Bumetanide | Bumetanide | 28 | 13 |
| Nystatin | Nystatin | 28 | 11 |
| Colchicine | Colchicine | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Fluconazole | Fluconazole | 24 | 16 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 19 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 11 |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Volnea | Desog-E.Estradiol/E.Estradiol | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $755.72 · 41 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE INSULINX, FREESTYLE LIBRE 3, Flexitouch Plus, IBSRELA, JARDIANCE, MINIMED 780G, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PREVNAR 20, REPATHA, RINVOQ, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VYEPTI, XIFAXAN, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error